NMDA receptor modulator 9 

NMDA receptor modulator 9 is an orally active NMDA receptor positive allosteric modulator (PAM). NMDA receptor modulator 9 enhances GluN2A receptor activity. NMDA receptor modulator 9 demonstrates significant antidepressant-like effects in chronic restraint stress (CRS)-induced depression mice. NMDA receptor modulator 9 can be used for the study of depression^[1].

NMDA receptor modulator 9 (Compound Y36) (30 μM) significantly enhances GluN2A receptor-mediated currents only when coadministered with both glutamate and Glycine (HY-Y0966) in Xenopus oocytes expressing GluN1/GluN2A^[1].
NMDA receptor modulator 9 shows higher efficacy (E_max = 397.7%) than GNE-3419 (E_max = 196.4%), reducing the EC₅₀ values and increasing the E_max values for glutamate/Glycine at GluN2A receptor^[1].
NMDA receptor modulator 9 (200 μM) exhibits no significant cytotoxicity in HEK293, PC12, and SH-SY5Y cell lines^[1].
NMDA receptor modulator 9 exhibits weak affinity for the hERG channel with an IC₅₀ of 67.85 μM, indicating low risk of cardiac toxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

NMDA receptor modulator 9 (Compound Y36) (0.1-1.0 mg/kg, i.p. or p.o., single dose) alleviates depression-related behaviors in chronic restraint stress (CRS) mice^[1].
NMDA receptor modulator 9 (Compound Y36) (200-350 mg/kg, p.o., single dose) exhibits slow mortality with an LD₅₀ of 270.82 mg/kg in male C57BL/6J mice^[1].
NMDA receptor modulator 9 (0.3-1.0 mg/kg, i.p., every 2 days for 30 days) causes no abnormal behavior, stable body weight, no significant changes in organ/body weight ratios, and no obvious nephrotoxicity, hepatotoxicity or myocardial injury in ICR mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

373.44

C₁₉H₂₀FN₃O₂S

FC1=CC=C(C2(O)CCN(CC3=CC(N4C=C(SC4=N3)C)=O)CC2)C=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yang T, et al. AI-Driven Discovery and Optimization of Positive Allosteric Modulators for NMDA Receptors: Potential Applications in Depression. J Med Chem. 2025 Aug 14;68(15):16260-16283.  [Content Brief]